GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ultragenyx Pharmaceutical Inc (NAS:RARE) » Definitions » EV-to-Revenue

Ultragenyx Pharmaceutical (Ultragenyx Pharmaceutical) EV-to-Revenue

: 6.99 (As of Today)
View and export this data going back to 2014. Start your Free Trial

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Ultragenyx Pharmaceutical's enterprise value is $3,035.2 Mil. Ultragenyx Pharmaceutical's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $434.2 Mil. Therefore, Ultragenyx Pharmaceutical's EV-to-Revenue for today is 6.99.

The historical rank and industry rank for Ultragenyx Pharmaceutical's EV-to-Revenue or its related term are showing as below:

RARE' s EV-to-Revenue Range Over the Past 10 Years
Min: 4.71   Med: 25.29   Max: 24209.28
Current: 6.99

During the past 13 years, the highest EV-to-Revenue of Ultragenyx Pharmaceutical was 24209.28. The lowest was 4.71. And the median was 25.29.

RARE's EV-to-Revenue is ranked better than
51.21% of 1031 companies
in the Biotechnology industry
Industry Median: 7.58 vs RARE: 6.99

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-04-19), Ultragenyx Pharmaceutical's stock price is $42.37. Ultragenyx Pharmaceutical's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $5.89. Therefore, Ultragenyx Pharmaceutical's PS Ratio for today is 7.19.


Ultragenyx Pharmaceutical EV-to-Revenue Historical Data

The historical data trend for Ultragenyx Pharmaceutical's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ultragenyx Pharmaceutical Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-Revenue
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 16.89 29.87 14.61 6.98 7.83

Ultragenyx Pharmaceutical Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-Revenue Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.98 5.82 6.88 5.31 7.83

Competitive Comparison

For the Biotechnology subindustry, Ultragenyx Pharmaceutical's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ultragenyx Pharmaceutical EV-to-Revenue Distribution

For the Biotechnology industry and Healthcare sector, Ultragenyx Pharmaceutical's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Ultragenyx Pharmaceutical's EV-to-Revenue falls into.



Ultragenyx Pharmaceutical EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Ultragenyx Pharmaceutical's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=3035.212/434.249
=6.99

Ultragenyx Pharmaceutical's current Enterprise Value is $3,035.2 Mil.
Ultragenyx Pharmaceutical's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $434.2 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ultragenyx Pharmaceutical  (NAS:RARE) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Ultragenyx Pharmaceutical's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=42.37/5.893
=7.19

Ultragenyx Pharmaceutical's share price for today is $42.37.
Ultragenyx Pharmaceutical's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $5.89.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ultragenyx Pharmaceutical EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Ultragenyx Pharmaceutical's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Ultragenyx Pharmaceutical (Ultragenyx Pharmaceutical) Business Description

Traded in Other Exchanges
Address
60 Leveroni Court, Novato, CA, USA, 94949
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.
Executives
Emil D Kakkis director, 10 percent owner, officer: President & CEO C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Thomas Richard Kassberg officer: CBO & Senior Vice President C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Howard Horn officer: Chief Financial Officer C/O VIR BIOTECHNOLOGY, INC., 499 ILLINOIS STREET, SUITE 500, SAN FRANCISCO CA 94158
Theodore Alan Huizenga officer: Controller and PAO C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Erik Harris officer: EVP & Chief Commercial Officer 60 LEVERONI COURT, NOVATO CA 94949
Sanders Corazon (corsee) D. director C/O MOLECULAR TEMPLATES, INC., 9301 AMBERGLEN BLVD, SUITE 100, AUSTIN VI 78729
John Richard Pinion officer: See Remarks C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Karah Herdman Parschauer officer: EVP and General Counsel 60 LEVERONI COURT, NOVATO CA 94949
Eric Crombez officer: EVP and Chief Medical Officer C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Dennis Karl Huang officer: SVP and Chief Tech Ops Officer C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Camille L Bedrosian officer: EVP and Chief Medical Officer C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Mardi Dier officer: CFO & Executive Vice President C/O ACELYRIN, INC., 4149 LIBERTY CANYON RD., AGOURA HILLS CA 91301
Amrit Ray director 60 LEVERONI COURT, NOVATO CA 94949
William Aliski director C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Shalini Sharp officer: CFO & Senior Vice President C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949